Abstract 2336: Clinical-pathological characterization of the immunomodulator subgroup of triple negative breast cancer as a promising step in the selection of patients in personalized immunotherapies
Abstract Introduction: Triple Negative Breast Cancer (CMTN) represents 23.1% of breast cancer cases in Mexico, is defined as a tumor that is absent of hormone receptors (estrogen and progesterone) and low HER2 overexpression and clinically is characterized by its agressive tumoral behavior. Lehmann...
Saved in:
| Published in: | Cancer research (Chicago, Ill.) Vol. 79; no. 13_Supplement; p. 2336 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
01-07-2019
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract
Introduction: Triple Negative Breast Cancer (CMTN) represents 23.1% of breast cancer cases in Mexico, is defined as a tumor that is absent of hormone receptors (estrogen and progesterone) and low HER2 overexpression and clinically is characterized by its agressive tumoral behavior.
Lehmann et al. described an immunomodulatory (IM) group which is composed of genes for immune antigens and transduction pathways of immune signals and cytokines. Recent studies have shown that patients with the IM phenotype have a better prognosis. So it is important to continue with the description of this subgroup as the first step for personalized therapies in this heterogeneous tumor.
Methodology: Retrospective clinical study, patients with diagnosis of CMTN, attended at the National Cancer Institute of Mexico (Total: 69 patients) were included. Following, the extraction of RNA from the primary tumor tissue of CMTN paraffin blocks was performed to subsequently generate labeled cDNA for hybridization in Affymetrix® Human Gene 2.0 microarrays, to later carry out the scanning and analysis of the data. For the analysis of microarrays we used the free software R and Bioconductor.65. And then the classification of patients using the platform "TNBCtype (http://cbc.mc.vanderbilt.edu/tnbc/)". And finally the analysis of survival, univariate and multivariate through SPSS.
Results: We observed some clinical variables with statistical difference such as radiotherapy (p<0.001), metastasis to lung (p=0.009), liver (p=0.013), and central nervous system (p=0.0029), as well as the Lehmann classifier showed significant difference between patients classified as IM vs. No IM (p=0.04).
Conclusions: the IM classifier could not only serve as an excellent prognostic classification in CMTN but as a predictor of immunological treatments.
Citation Format: Ruben R. Bautista, Oscar Gerardo A. Rodríguez, Alfredo H. Miranda, Alejandro Z. Dehesa. Clinical-pathological characterization of the immunomodulator subgroup of triple negative breast cancer as a promising step in the selection of patients in personalized immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2336. |
|---|---|
| ISSN: | 0008-5472 1538-7445 |
| DOI: | 10.1158/1538-7445.AM2019-2336 |